The evolution of Alzheimer’s target identification: Towards a fusion of artificial and cellular intelligence
Gayle Wittenberg(Johnson & Johnson (United States)), Simon Lovestone(Johnson & Johnson (United Kingdom)), Fiona Elwood(Novartis (Switzerland)), Tommaso Mansi(Johnson & Johnson (United States)), Bart Smets
Cited by 0
Related Papers
Tau molecular diversity contributes to clinical heterogeneity in Alzheimer’s disease
|Nature Medicine|2020|445
The Global Neurodegeneration Proteomics Consortium: biomarker and drug target discovery for common neurodegenerative diseases and aging
|Nature Medicine|2025|85
TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels
|Alzheimer s & Dementia|2021|43
Genome-wide CRISPR screen identifies protein pathways modulating tau protein levels in neurons
|Communications Biology|2021|30
Blood DNA methylomic signatures associated with CSF biomarkers of Alzheimer's disease in the EMIF‐AD study
|Alzheimer s & Dementia|2024|16